Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical Company (NASDAQ: STAA) will announce its financial results for the first quarter ended April 2, 2021, on May 5, 2021, after the market close. A conference call to discuss these results is scheduled for the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Participants can join the call by dialing 833-350-1429 (domestic) or 647-689-6661 (international). A replay will be available for seven days after the call. STAAR specializes in implantable lenses for eye surgery, with over 1,000,000 lenses implanted globally.
STAAR Surgical Company (NASDAQ: STAA) reported financial results for Q4 and FY 2020, highlighting a net sales increase of 18% to $46.0 million for Q4, driven by a 20% rise in ICL sales. However, net income fell to $0.07 per share from $0.14 due to a prior year tax benefit. For FY 2020, net sales reached $163.5 million, up 9%, but gross margin decreased to 72.4%. Operating expenses rose to $111.6 million due to increased costs across various areas, including R&D. The company remains optimistic about ongoing growth and market share gains in refractive procedures.
STAAR Surgical Company (NASDAQ: STAA) has announced it will release its fourth-quarter and fiscal year financial results on February 24, 2021, post-market. The company will also hold a conference call at 4:30 p.m. Eastern to discuss these results and operational insights. STAAR specializes in developing and marketing implantable lenses and delivery systems for the eye, with over 1,000,000 Visian® ICLs implanted globally, illustrating its strong presence in the ophthalmic surgery market.
STAAR Surgical Company (NASDAQ: STAA) has appointed Elizabeth Yeu, M.D. and K. Peony Yu, M.D. to its Board of Directors, effective January 21, 2021. Their addition highlights the company's commitment to excellence and growth in the field of ophthalmology. Yeu is a respected ophthalmic surgeon with extensive leadership experience, while Yu has over 25 years in biomedical leadership, having served as Chief Medical Officer at FibroGen. John Moore, a board member since 2008, will retire at the 2021 Annual Shareholders Meeting. The new appointments aim to enhance STAAR's strategic goals in refractive vision correction.
STAAR Surgical Company (NASDAQ: STAA) announced preliminary fourth quarter and fiscal year results for the period ending January 1, 2021. Expected total net sales are approximately $46 million for Q4 and $163 million for the full year. GAAP earnings per share is projected to be around $0.06 for Q4 and $0.12 for the fiscal year. The company reported a rise in ICL units across various regions, with significant growth in countries like China and Japan. STAAR plans to advance commercialization of its EVO product initiatives and maintain a growth target of 25% compound annual revenue increase over three years.
STAAR Surgical Company (NASDAQ: STAA) has announced the successful initial commercialization of its EVO Viva™ lens, specifically targeting presbyopia patients. The first implantation occurred on October 23 in Belgium and received positive feedback. This lens aims to provide visual freedom for individuals aged 40-50 struggling with near vision. Consumer websites in multiple languages are active, and clinical data supporting the lens's efficacy has been published. The company plans to collaborate with surgeons to optimize the product’s integration in clinical practice.
STAAR Surgical Company (NASDAQ: STAA) reported a strong performance for Q3 2020, achieving record net sales of $47.1 million, up 21% year-over-year. Key drivers include ICL sales of $41.5 million, representing a 23% increase, and a 25% rise in ICL units sold. Gross margin was 74.1%, slightly lower than 74.4% in Q3 2019. Net income rose to $3.9 million or $0.08 per share from $2.4 million or $0.05 per share in the prior year. Cash reserves increased to $128.3 million. Despite strong growth, markets in India and the Middle East were adversely affected by COVID-19.
STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the third quarter ended October 2, 2020, on November 4, 2020, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Interested parties can access the call at 833-350-1429 (domestic) or 647-689-6661 (international). A replay and archived webcast will be available shortly after the call. STAAR specializes in implantable lenses and has marketed over 1,000,000 Visian® ICLs worldwide.